Certis Oncology Solutions
Certis Oncology Solutions provides predictive therapeutic response data to help select and develop cancer treatments. The company produces Oncology Intelligence® by testing candidate drugs in clinically relevant patient-derived tumor models and analyzing results with CertisAI, its proprietary machine learning and AI platform. Its offerings include functional precision medicine (YourPDX testing), annotated preclinical models, custom study design, and advanced imaging with image-guided irradiation. Certis serves oncologists and therapeutics developers as a translational life-sciences services and analytics provider and holds clinical laboratory certifications for high-complexity testing.
Certis Oncology Solutions
Certis Oncology Solutions provides predictive therapeutic response data to help select and develop cancer treatments. The company produces Oncology Intelligence® by testing candidate drugs in clinically relevant patient-derived tumor models and analyzing results with CertisAI, its proprietary machine learning and AI platform. Its offerings include functional precision medicine (YourPDX testing), annotated preclinical models, custom study design, and advanced imaging with image-guided irradiation. Certis serves oncologists and therapeutics developers as a translational life-sciences services and analytics provider and holds clinical laboratory certifications for high-complexity testing.
TL;DR
Founded: 2016
Headquarters: San Diego, CA
Core offering: Predictive therapeutic response using patient-derived tumor models + AI/ML
Last funding: Series C, $10M (Jan 17, 2024)
Clinical lab status: CLIA-certified laboratory
Company Overview
Problem Domain
Predicting cancer therapeutic response to improve personalized treatment selection and accelerate oncology drug development.
Founded
2016
Industry
Biotechnology
Tech Stack
Funding Track Record
10000000
Company announced closing of $10M Series C and named John R. Tozzi Chairman of the Board; press materials state participation from existing investors.
Investor Signal
“Incite Ventures led Series C; strong participation from existing investors as stated in company materials.”